Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit

Authors:

Abstract
No abstract available
Funding Information
  • F. Hoffmann-La Roche Belgium

This publication has 11 references indexed in Scilit: